These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 8747409

  • 21. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M.
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [Abstract] [Full Text] [Related]

  • 22. CYP2D6 genotype determination in the Danish population.
    Brøsen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K.
    Eur J Clin Pharmacol; 1994 Apr; 47(3):221-5. PubMed ID: 7867674
    [Abstract] [Full Text] [Related]

  • 23. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
    Evert B, Griese EU, Eichelbaum M.
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
    [Abstract] [Full Text] [Related]

  • 24. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
    Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R.
    Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140
    [Abstract] [Full Text] [Related]

  • 25. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B.
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [Abstract] [Full Text] [Related]

  • 26. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA.
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [Abstract] [Full Text] [Related]

  • 27. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
    Løvlie R, Daly AK, Molven A, Idle JR, Steen VM.
    FEBS Lett; 1996 Aug 19; 392(1):30-4. PubMed ID: 8769309
    [Abstract] [Full Text] [Related]

  • 28. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
    Daly AK, Leathart JB, London SJ, Idle JR.
    Hum Genet; 1995 Mar 19; 95(3):337-41. PubMed ID: 7868129
    [Abstract] [Full Text] [Related]

  • 29. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
    Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K.
    Pharmacogenetics; 1998 Apr 19; 8(2):119-23. PubMed ID: 10022749
    [Abstract] [Full Text] [Related]

  • 30. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA.
    Carcinogenesis; 1994 Sep 19; 15(9):1955-61. PubMed ID: 7923590
    [Abstract] [Full Text] [Related]

  • 31. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.
    Panserat S, Mura C, Gérard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R.
    Hum Genet; 1994 Oct 19; 94(4):401-6. PubMed ID: 7927337
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Weston A, Harris CC.
    Carcinogenesis; 1990 Sep 19; 11(9):1527-30. PubMed ID: 1976046
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Novel mutations of CYP3A4 in Chinese.
    Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD.
    Drug Metab Dispos; 2001 Mar 19; 29(3):268-73. PubMed ID: 11181494
    [Abstract] [Full Text] [Related]

  • 37. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
    Roots I, Brockmöller J, Drakoulis N, Loddenkemper R.
    Clin Investig; 1992 Mar 19; 70(3-4):307-19. PubMed ID: 1355678
    [Abstract] [Full Text] [Related]

  • 38. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
    Heim MH, Meyer UA.
    Methods Enzymol; 1991 Mar 19; 206():173-83. PubMed ID: 1686063
    [No Abstract] [Full Text] [Related]

  • 39. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M.
    Mol Pharmacol; 1994 Sep 19; 46(3):452-9. PubMed ID: 7935325
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.